Climb Bio, Inc. Common Stock

CLYMNASDAQ • USD
ThemeBiotech - Drug Development›Immunology & Autoimmune
14.11 USD
↗ 0.20 (1.44%)AT CLOSE (11:59 AM EDT)
13.96
↘ 0.15 (1.10%)
POST MARKET (AS OF 07:30 PM EDT)
Post Market
AS OF 07:30 PM EDT
13.96
↘ 0.15 (1.10%)
🔴Market: CLOSED

Shares of Climb Bio, Inc. Common Stock (CLYM) are trading at $14.11. Our models show a "Sell" technical signal alongside a "Neutral" fundamental rating. Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. CLYM is fairly valued relative to its sector peers based on current multiples.

Technical & fundamental data as of Sep 16, 2026.

Open?$14.00
High?$14.55
Low?$13.87
Prev. Close?$13.91
Volume?2.6M
Avg. Volume?1.5M
VWAP?$14.22
Rel. Volume?1.71x
Bid / Ask
Bid?$13.53 × 100
Ask?$14.50 × 3.0K
Spread?$0.97
Midpoint?$14.02
Valuation & Ratios
Market Cap?810.4M
Shares Out?57.4M
Float?20.0M
Float %?41.8%
P/E Ratio?N/A
P/B Ratio?3.38
EPS?-$1.00
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
Themes
Biotech - Drug Development›Immunology & AutoimmuneBiotech - Drug Development›Rare Disease Therapeutics
Employees
29
Market Cap
798.9M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.climbbio.com
Listed
2021-08-10
Address
20 WILLIAM STREET
WELLESLEY HILLS, MA 02481
Phone: 1-866-857-2596
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
50
Short Sent.?
42
Piotroski F-Score?0/9Weak
Altman Z-Score?70.28Safe
Confidence?41%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?36.59%Squeeze Risk
Short Interest?7.3M
Days to Cover?5.9
Free Float20.0M
Avg Daily Volume1.2M
Settlement Date2026-08-31
Financial Health
Current Ratio?31.45Strong
Quick Ratio?31.45Strong
Cash Ratio?7.43Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A▾
P/B?
Peers
100
S&P
50
3.38FAIR▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-11.9CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
7
-24.1%WEAK▾
ROA?
S&P
3
-23.4%WEAK▾
Cash Flow & Enterprise
FCF?$-53068000
Enterprise Value?$766.3M
Fundamentals ratios updated end of day
MarketsMoversWatchlist